Treatment patterns and blood count control in 10,112 patients with polycythemia vera.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-07-01 Epub Date: 2025-06-26 DOI:10.1080/17474086.2025.2520316

Naveen Pemmaraju, Jingbo Yu, Anupama Vasudevan, Husain Qureshi, Evan Braunstein, Aleksander Chojecki

{"title":"Treatment patterns and blood count control in 10,112 patients with polycythemia vera.","authors":"Naveen Pemmaraju, Jingbo Yu, Anupama Vasudevan, Husain Qureshi, Evan Braunstein, Aleksander Chojecki","doi":"10.1080/17474086.2025.2520316","DOIUrl":null,"url":null,"abstract":"Background: Elevated blood counts in polycythemia vera (PV) are associated with increased thrombotic risk, which contributes to morbidity and mortality.Research design and methods: This retrospective study describes treatment patterns and blood count control in patients with PV managed at community oncology practices (January 2014-February 2023; Integra Precision Q database).Results: Of a total 10,112 patients, most received phlebotomy (68.1%) or hydroxyurea (HU; 28.2%) as initial treatment, with median follow-up of 32.1 (IQR, 13.5-58.5) months and 31.5 (IQR, 16.8-54.9) months, respectively. Changing treatment was less common than remaining on initial treatment despite 67.8% of patients on phlebotomy and 30.4% on HU having elevated hematocrit (≥45%) after 1 year of treatment. In contrast, 85.4% of patients who switched to ruxolitinib from HU achieved hematocrit < 45% after 1 year, and fewer required phlebotomy during ruxolitinib treatment than with HU treatment (RUX, 29.3%; HU, 53.5%). Additionally, 54.2% of patients who switched to ruxolitinib achieved white blood cell counts < 11 × 109/L, and 57.5% achieved platelet counts ≤ 400 × 109/L after 1 year of ruxolitinib treatment.Conclusions: This real-world evidence highlights the importance of considering alternative therapies for patients whose initial treatment regimen does not provide adequate clinical benefit.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"529-536"},"PeriodicalIF":2.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2520316","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Elevated blood counts in polycythemia vera (PV) are associated with increased thrombotic risk, which contributes to morbidity and mortality.

Research design and methods: This retrospective study describes treatment patterns and blood count control in patients with PV managed at community oncology practices (January 2014-February 2023; Integra Precision Q database).

Results: Of a total 10,112 patients, most received phlebotomy (68.1%) or hydroxyurea (HU; 28.2%) as initial treatment, with median follow-up of 32.1 (IQR, 13.5-58.5) months and 31.5 (IQR, 16.8-54.9) months, respectively. Changing treatment was less common than remaining on initial treatment despite 67.8% of patients on phlebotomy and 30.4% on HU having elevated hematocrit (≥45%) after 1 year of treatment. In contrast, 85.4% of patients who switched to ruxolitinib from HU achieved hematocrit < 45% after 1 year, and fewer required phlebotomy during ruxolitinib treatment than with HU treatment (RUX, 29.3%; HU, 53.5%). Additionally, 54.2% of patients who switched to ruxolitinib achieved white blood cell counts < 11 × 10⁹/L, and 57.5% achieved platelet counts ≤ 400 × 10⁹/L after 1 year of ruxolitinib treatment.

Conclusions: This real-world evidence highlights the importance of considering alternative therapies for patients whose initial treatment regimen does not provide adequate clinical benefit.

查看原文本刊更多论文

真性红细胞增多症10112例的治疗模式和血细胞计数控制。

背景：真性红细胞增多症（PV）的血细胞计数升高与血栓形成风险增加相关，从而增加发病率和死亡率。研究设计和方法：本回顾性研究描述了社区肿瘤学实践中PV患者的治疗模式和血细胞计数控制(2014年1月- 2023年2月；Integra Precision Q数据库)。结果：10112例患者中，大多数接受了放血（68.1%）或羟基脲(HU；28.2%)作为初始治疗，中位随访时间分别为32.1 （IQR, 13.5-58.5）个月和31.5 （IQR, 16.8-54.9）个月。尽管67.8%的静脉切开术患者和30.4%的HU患者在治疗1年后红细胞压积升高（≥45%），但改变治疗比保持初始治疗更少见。相比之下，从HU切换到ruxolitinib的患者中，85.4%的患者在ruxolitinib治疗1年后达到血细胞比压9/L， 57.5%的患者血小板计数≤400 × 109/L。结论：这一真实世界的证据强调了对初始治疗方案不能提供足够临床益处的患者考虑替代疗法的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.